KRYS
NASDAQKrystal Biotech Inc.
Price$302.27+10.96 (+3.76%)
01:30 PM03:30 PM
News · 26 weeks48-57%
2025-12-072026-05-31
Mix1990d
- Insider5(26%)
- Other5(26%)
- SEC Filings4(21%)
- Earnings3(16%)
- Leadership1(5%)
- Analyst1(5%)
Latest news
25 items- INSIDEREVP, General Counsel Thomas John Charles sold $193,903 worth of shares (642 units at $302.03) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- PRCorbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference CallNORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team will host a conference call and webcast on Tuesday, May 26 at 8:00 a.m. EDT to discuss updated data for its Phase 1/2 study of CRB-701, a next-generation Nectin-4 antibody drug candidate (ADC), in both head and neck squamous cell carcinoma (HNSCC) as well as cervical cancer. The data, which will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, represent an April 1, 2026 data cut, and will include cli
- PRKrystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis BullosaVYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB PITTSBURGH, May 18, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that, on May 15, 2026, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (CO
- PRKrystal Biotech to Present at BofA Securities 2026 Health Care ConferencePITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 11:20 am PT on Wednesday, May 13, 2026 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biotechnology comp
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Krystal Biotech Inc.SCHEDULE 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
- SECKrystal Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Krystal Biotech, Inc. (0001711279) (Filer)
- SECSEC Form 10-Q filed by Krystal Biotech Inc.10-Q - Krystal Biotech, Inc. (0001711279) (Filer)
- PRKrystal Biotech Announces First Quarter 2026 Financial and Operating Results$116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) registrational data readouts in 2026 FDA grants platform technology designation for KB407 (CF) and KB111 (HHD) Strong balance sheet, ending the quarter with $1.0 billion in cash and investments PITTSBURGH, May 04, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the first quarter ending March 31, 2026 and provided a business update. "Following a successful 2025, we are entering 2026 with strong momentum, including two potential
- PRKrystal Biotech to Present at Upcoming Scientific ConferencesPITTSBURGH, April 30, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that the Company will be presenting on multiple programs at upcoming scientific conferences being held in May and June. Presentation details are outlined below. American Society of Gene & Cell Therapy (ASGCT) 2026 Annual MeetingPoster Presentation Title: Evaluation of KB409 and KB410, two HSV-1-based gene therapy vectors for the treatment of primary ciliary dyskinesia (PCD)Presenter: Bruce Nmezi, PhDDate and Time: May 12, 2026 from 5:00PM to 6:30PM ET American Thoracic Society (ATS) International Conference 2026Oral Presentation Title: Interim results of the CORAL-1 trial
- PRKrystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, May 4, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53916. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's website at www.krystalbio.com. A
- SECSEC Form DEFA14A filed by Krystal Biotech Inc.DEFA14A - Krystal Biotech, Inc. (0001711279) (Filer)
- SECSEC Form DEF 14A filed by Krystal Biotech Inc.DEF 14A - Krystal Biotech, Inc. (0001711279) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Krystal Biotech Inc.SCHEDULE 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)
- ANALYSTWolfe Research initiated coverage on Krystal BiotechWolfe Research initiated coverage of Krystal Biotech with a rating of Peer Perform
- PRPalvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient ServicesMs. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025 Ms. McDonough to lead Palvella's Market Access and Patient Services organizations, advancing payer engagement, patient support, specialty distribution, and access strategy for the Company's QTORIN™ programs targeting serious, rare skin diseases and vascular malformations WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceut
- INSIDERNew insider Goux Laurent Louis Jean claimed ownership of 919 shares (SEC Form 3)3 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERNew insider Thomas John Charles claimed ownership of 642 shares (SEC Form 3)3 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident, R&D Krishnan Suma sold $6,580,270 worth of shares (25,000 units at $263.21), decreasing direct ownership by 2% to 1,403,155 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident and CEO Krishnan Krish S sold $6,579,164 worth of shares (25,000 units at $263.17), decreasing direct ownership by 2% to 1,475,253 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- SECSEC Form 144 filed by Krystal Biotech Inc.144 - Krystal Biotech, Inc. (0001711279) (Subject)
- SECSEC Form 144 filed by Krystal Biotech Inc.144 - Krystal Biotech, Inc. (0001711279) (Subject)
- INSIDERChief Accounting Officer Romano Kathryn converted options into 8,050 shares, covered exercise/tax liability with 3,502 shares and sold $200,700 worth of shares (750 units at $267.60), increasing direct ownership by 20% to 22,366 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident, R&D Krishnan Suma converted options into 67,225 shares and covered exercise/tax liability with 30,584 shares, increasing direct ownership by 1% to 1,428,155 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERPresident and CEO Krishnan Krish S covered exercise/tax liability with 30,584 shares and converted options into 67,225 shares, increasing direct ownership by 2% to 1,500,253 units (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
- INSIDERDirector Janney Daniel sold $3,252,824 worth of shares (11,803 units at $275.59) (SEC Form 4)4 - Krystal Biotech, Inc. (0001711279) (Issuer)
KRYS FAQ
7 questionsWhat does Krystal Biotech Inc. do?
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and acne scars; KB407 that is in preclinical stage for cystic...Where does KRYS stock trade?
Krystal Biotech Inc. (KRYS) is listed on NASDAQ.What sector and industry is KRYS in?
Krystal Biotech Inc. operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Krystal Biotech Inc. go public?
Krystal Biotech Inc. (KRYS) completed its IPO in 2017.What are analysts saying about KRYS?
Krystal Biotech Inc. has had 8 recent analyst actions on file. The most recent action was from Wolfe Research: Peer Perform on 2026-03-27.What companies are similar to KRYS?
Notable peers in the same industry include LEGN (Legend Biotech Corporation), PRTG (Portage Biotech Inc.), EDSA (Edesa Biotech Inc.), BBI (Brickell Biotech Inc.), MBRX (Moleculin Biotech Inc.). Compare KRYS side-by-side with any of them on Quantisnow.How can I track KRYS on Quantisnow?
Quantisnow aggregates Krystal Biotech Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow KRYS to receive live email and push alerts on every new disclosure.